Company profile · free preview

BIO-key International, Inc.

BKYI · NASDAQ · Technology · Updated 10/25/2026

Revenue

—

Fiscal 2025

Net income

(7.2M)

Fiscal 2025

Free cash flow

(4.7M)

Fiscal 2025

Net cash / (debt)

—

Fiscal 2025

Five-year financials

Fiscal year20252024202320222021
Revenue—————
Net income(7.2M)(4.3M)(1.7M)(11.9M)(5.1M)
Diluted EPS—————
Operating cash flow(4.7M)(2.9M)(3.8M)(6.2M)(9.0M)
Free cash flow(4.7M)(2.9M)(3.8M)(6.3M)(9.0M)
Cash$2.7M$437604$511400$2.6M$7.8M
Total debt—————

Where the cash went

Cumulative, fiscal 2021–2025, straight from the reported cash-flow statements.

Reinvested in capex

—

of operating cash flow

Returned to owners

—

of free cash flow (buybacks + dividends)

Diluted share count

—

change 2021–2025

Capital expenditure $150123Bar width = share of $150123 (spending exceeded operating cash flow)
Operating cash flow($26.6M)
Capital expenditure($150123)
Free cash flow($26.7M)
Share buybacks—
Dividends paid—
Acquisitions (net)—
Net debt issued / (repaid)—
Stock-based compensation (non-cash)—

"—" means a year didn't report that line, so no total is shown rather than an estimate.

SEC filings

No filings stored yet.

Ask anything about BIO-key International, Inc.'s filings

"What changed since last year?" "Where is the cash going?" Get answers drawn straight from the filings.

Start researching free

More companies